940 participants
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-29
- Start Date:
- 2017-02-21
- Completion:
- 2029-03-30
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- DRUG
No Results Yet